There are 2789 resources available
592P - Bipolar androgen therapy (BAT) plus olaparib in men with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Michael Schweizer
Session: ePoster Display
593P - Pain efficacy with radium-223 (Ra-223) in the REASSURE global, prospective, observational study of men with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Celestia Higano
Session: ePoster Display
594P - Pain efficacy with radium-223 (Ra-223) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the PARABO observational study
Presenter: Holger Palmedo
Session: ePoster Display
595P - Correlation between genomic alterations and germline mutations in men with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Casilda Llacer Perez
Session: ePoster Display
541P - Ezabenlimab (BI 754091), an anti-PD-1 antibody, in combination with BI 836880, a VEGF/Ang2-blocking nanobody, in patients (pts) with previously treated advanced solid tumours
Presenter: Maen Hussein
Session: ePoster Display
542P - Ezabenlimab (BI 754091) monotherapy in patients (pts) with advanced solid tumours
Presenter: Manish Patel
Session: ePoster Display
543P - Neoadjuvant MRx0518 treatment is associated with significant gene and metagene signature changes in solid tumours
Presenter: Mark Lythgoe
Session: ePoster Display
544P - A novel HER2/4-1BB bispecific antibody, YH32367 (ABL105) exerts significant anti-tumor effects through tumor-directed T cell activation
Presenter: Eunjung Lee
Session: ePoster Display
545P - First-in-human (FIH) study of E7130 in patients (pts) with advanced solid tumors: Primary result of dose-escalation part
Presenter: Toshihiko Doi
Session: ePoster Display
603P - Objective computerized cognitive assessment in men with metastatic castrate-resistant prostate cancer (mCRPC) randomly receiving darolutamide or enzalutamide in the ODENZA trial
Presenter: Emeline Colomba
Session: ePoster Display